| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8957763 | Critical Reviews in Oncology/Hematology | 2018 | 6 Pages |
Abstract
Currently, SBRT might be considered a treatment alternative in inoperable patients affected by primary RCC. Currently, dose-escalation to 48âGy in 3-4 fractions are effective and well tolerated. Emerging role of immune therapies in RCC patients warrant further studies to explore interactions between SBRT and immune response.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Hematology
Authors
G. Francolini, B. Detti, G. Ingrosso, I. Desideri, C. Becherini, G. Carta, D. Pezzulla, G. Caramia, L. Dominici, V. Maragna, M.A. Teriaca, M. Bottero, L. Livi,